Blistering First Half For Sepha......and a six-figure deal with Global Pharmaceutical giant Novartis.
The Enterprise Equity backed pharmaceutical engineering company, Sepha Ltd, has announced a strong half-year sales performance for the six months ended March 2012 which includes new orders from the pharmaceutical giant, Novartis, for their leak inspection machine, Visionscan.
Performance at the half-way stage puts the company on target for a 30% increase in sales at the end of the current financial year and comes on the back of a previous 30% sales increase at the end of the previous financial year. The growth has also resulted in a 25% increase in employment on the previous year.
Sepha's sales success has been fuelled by the launch of a range of innovative machines that use high resolution imaging technology to detect product defects in pharmaceutical blister packs. The order from the Swiss-based pharmaceutical company, Novartis, for one of these new machines is seen as a significant achievement by the Sepha team who designed and developed Visionscan at their Belfast based R&D facility. Visionscan is the world’s first tool-less inspection machine for detecting leaks in pharmaceutical blister packs.
Since its launch last year, Sepha has achieved export sales for Visionscan in all its major global markets including USA, Brazil, India, Europe and even New Zealand. Paul Kelly, Head of Sales and Marketing said, “Combined with extensive export sales and marketing support for our existing product ranges, the introduction of Visionscan has enabled us to win new business with global pharmaceutical clients. Over the last five years there have been considerable changes in global pharmaceutical production, with significant production cost-saving measures implemented by most large drug producers. We developed our new range to respond to these developments. Visionscan enables pharmaceutical manufacturers to significantly lower their production costs while at the same time improving their quality levels.”
Exports currently contribute over 95% of Sepha’s turnover. The company already has a global customer base that includes many of the top global pharmaceutical companies. << BACK